Jennifer Lachey, Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 4,980 shares at $54.45 ($268K) on 2022-01-11, disclosed to the SEC on 2022-01-13.
Open-market sale of $268k KROS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $52.01 | 320 | $17K | 6.2% |
| 2 | $53.56 | 1,196 | $64K | 23.9% |
| 3 | $53.56 | 1,196 | $64K | 23.9% |
| 4 | $54.45 | 1,134 | $62K | 23.0% |
| 5 | $54.45 | 1,134 | $62K | 23.0% |
| Total | $53.87 avg | 4,980 |
| $268K |
| 100% |
| Filing → |
| KROS | SELL | 2022-05-13 | $362K | — | Filing → |
| KROS | SELL | 2022-04-13 | $630K | — | Filing → |
| KROS | SELL | 2022-04-06 | $477K | — | Filing → |